Goldman Sachs Downgrades Adeptus Biotechnologies Corp. (ADPT) to Neutral
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $24.74 +1.14%
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter downgraded Adeptus Biotechnologies Corp. (NASDAQ: ADPT) from Buy to Neutral with a price target of $63.00 (from $74.00).
For an analyst ratings summary and ratings history on Adeptus Biotechnologies Corp. click here. For more ratings news on Adeptus Biotechnologies Corp. click here.
Shares of Adeptus Biotechnologies Corp. closed at $53.11 yesterday.
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
- Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
